Lytix Biopharma third quarter 2022 results
Oslo, 17 November 2022. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immune-oncology company, today releases its third quarter 2022 results. Highlights include regulatory approval received to expand our ATLAS-IT-05 study to three European countries and the appointment of Stephen Worsley as CBO.“We are very pleased to now being able to include patients from Spain, France and Norway in our Phase II study. The expansion of the site network will mitigate recruitment challenges, drive enrollment towards completion and extend the clinical impact field for LTX-315”, says